{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:12:28Z","timestamp":1783383148743,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41409-019-0463-y","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T16:03:33Z","timestamp":1549296213000},"page":"1553-1561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin\u2019s lymphomas"],"prefix":"10.1038","volume":"54","author":[{"given":"Sara","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Abounader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don M.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Penza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Andritsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem M.","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bolwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4163-8823","authenticated-orcid":false,"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"463_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1200\/jco.1984.2.8.898","volume":"2","author":"JO Armitage","year":"1984","unstructured":"Armitage JO, Fyfe MA, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol. 1984;2:898\u2013902. \n                    https:\/\/doi.org\/10.1200\/jco.1984.2.8.898\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR2","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/s0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848\u201357. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(12)60605-9\n                    \n                  .","journal-title":"Lancet"},{"key":"463_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejm199309303291402","volume":"329","author":"S MA","year":"1993","unstructured":"MA S, DP H, JR A. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394. \n                    https:\/\/doi.org\/10.1056\/nejm199309303291402\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"463_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/nejm199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333:1540\u20135. \n                    https:\/\/doi.org\/10.1056\/nejm199512073332305\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"463_CR5","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/jco.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373\u201380. \n                    https:\/\/doi.org\/10.1200\/jco.2009.26.2493\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","volume":"20","author":"MD Caballero","year":"1997","unstructured":"Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451\u20138. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1700913\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"key":"463_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/jco.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1995;13:588\u201395. \n                    https:\/\/doi.org\/10.1200\/jco.1995.13.3.588\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","volume":"25","author":"EA Copelan","year":"2000","unstructured":"Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2000;25:1243\u20138. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1702433\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"key":"463_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/jco.1998.16.1.48","volume":"16","author":"PJ Stiff","year":"1998","unstructured":"Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin\u2019s lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998;16:48\u201355. \n                    https:\/\/doi.org\/10.1200\/jco.1998.16.1.48\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR10","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3109\/10428194.2015.1028054","volume":"56","author":"I Sakellari","year":"2015","unstructured":"Sakellari I, Mallouri D, Batsis I, Apostolou C, Konstantinou V, Abela EM, et al. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leuk Lymphoma. 2015;56:3071\u201381. \n                    https:\/\/doi.org\/10.3109\/10428194.2015.1028054\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"key":"463_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00277-001-0413-8","volume":"81","author":"M Hanel","year":"2002","unstructured":"Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81:96\u2013102. \n                    https:\/\/doi.org\/10.1007\/s00277-001-0413-8\n                    \n                  .","journal-title":"Ann Hematol"},{"key":"463_CR12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbmt.2006.03.016","volume":"12","author":"C Aggarwal","year":"2006","unstructured":"Aggarwal C, Gupta S, Vaughan WP, Saylors GB, Salzman DE, Katz RO, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770\u20137. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2006.03.016\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant"},{"key":"463_CR13","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1097\/MPH.0b013e3181fd6c79","volume":"33","author":"M Andion","year":"2011","unstructured":"Andion M, Molina B, Gonzalez-Vicent M, Alonso L, Hernandez C, Lassaletta A, et al. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. J Pediatr Hematol Oncol. 2011;33:e89\u201391. \n                    https:\/\/doi.org\/10.1097\/MPH.0b013e3181fd6c79\n                    \n                  .","journal-title":"J Pediatr Hematol Oncol"},{"key":"463_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2141.2009.07940.x","volume":"148","author":"RM Dean","year":"2010","unstructured":"Dean RM, Pohlman B, Sweetenham JW, Sobecks RM, Kalaycio ME, Smith SD, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol. 2010;148:226\u201334. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07940.x\n                    \n                  .","journal-title":"Br J Haematol"},{"key":"463_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","volume":"40","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2007;40:919\u201324. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1705841\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"key":"463_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bmt.1704637","volume":"34","author":"EH Wang","year":"2004","unstructured":"Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, et al. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant. 2004;34:581\u20137. \n                    https:\/\/doi.org\/10.1038\/sj.bmt.1704637\n                    \n                  .","journal-title":"Bone Marrow Transplant"},{"key":"463_CR17","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1080\/10428190802340184","volume":"49","author":"R Zaucha","year":"2008","unstructured":"Zaucha R, Gooley T, Holmberg L, Gopal AK, Press O, Maloney D, et al. High-dose chemotherapy with BEAM or Busulphan\/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma. 2008;49:1899\u2013906. \n                    https:\/\/doi.org\/10.1080\/10428190802340184\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"key":"463_CR18","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/1042819031000083028","volume":"44","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Kuittinen T, Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin\u2019s lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma. 2003;44:1151\u20138. \n                    https:\/\/doi.org\/10.1080\/1042819031000083028\n                    \n                  .","journal-title":"Leuk Lymphoma"},{"key":"463_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.leukres.2010.07.016","volume":"35","author":"JE Kim","year":"2011","unstructured":"Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011;35:183\u20137. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2010.07.016\n                    \n                  .","journal-title":"Leuk Res"},{"key":"463_CR20","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","volume":"22","author":"CR Flowers","year":"2016","unstructured":"Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes. Biol Blood Marrow Transplant. 2016;22:1197\u2013205. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.018\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant"},{"key":"463_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/jco.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. et al. NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244 \n                    https:\/\/doi.org\/10.1200\/jco.1999.17.4.1244\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","volume":"10","author":"JM Vose","year":"2004","unstructured":"Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10:116\u201327. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2003.09.015\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant"},{"key":"463_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/jco.1999.17.1.423","volume":"17","author":"MA Shipp","year":"1999","unstructured":"Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin\u2019s Lymphomas: report of the jury. J Clin Oncol. 1999;17:423\u20139. \n                    https:\/\/doi.org\/10.1200\/jco.1999.17.1.423\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR24","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/jco.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30:4462\u20139. \n                    https:\/\/doi.org\/10.1200\/jco.2012.41.9416\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"463_CR25","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdp237","volume":"20","author":"C Haioun","year":"2009","unstructured":"Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol. 2009;20:1985\u201392. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp237\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"463_CR26","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.bbmt.2016.06.011","volume":"22","author":"BT Hill","year":"2016","unstructured":"Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, et al. Daily weight-based busulfan with cyclophosphamide and etoposide produces comparable outcomes to four-times-daily busulfan dosing for lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:1588\u201395. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2016.06.011\n                    \n                  .","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0463-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:05Z","timestamp":1684617245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["463"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0463-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}